Vanderbilt Univeristy
Nashville, Tennessee, 37203, United States
NCT Number: NCT02730780
This study aims to assess the natriuretic peptide response to dietary salt loading in African-American individuals compared with white individuals.
Looking for future studies?
Notify Me18 year–55 year
All sexes
Interventional
Not applicable
Nashville, Tennessee, 37203, United States
High blood pressure, or hypertension, is a major cause of heart disease, heart failure, and stroke. Natriuretic peptides are cardiac derived hormones that may protect against hypertension. The classical actions of the natriuretic peptides include natriuresis, vasodilation, and inhibition of the renin-angiotensin-aldosterone system (RAAS), which support a key role for these hormones in blood pressure regulation.
Race based differences exist in the risk and severity of hypertension and cardiovascular disease, with African-American individuals typically being at greater risk compared with white individuals. Nearly half of African-American adults have hypertension, compared with one-third of whites. Additionally, salt-sensitivity denotes the impaired ability to handle a salt load with resulting increases in blood pressure. It is estimated that 75% of hypertensive African-Americans exhibit salt-sensitivity, compared with 35% of hypertensive whites. Why this predilection towards salt-sensitivity exists, particularly among African-American individuals, is not well understood. Thus, establishing the origins of salt retention in African Americans has biologic, preventative, and therapeutic importance, and may provide insight regarding racial differences in cardiovascular risk.
The natriuretic peptide system is the principal counter-regulatory mechanism to salt retention. However, little is known regarding racial differences in the natriuretic peptide system. Recently, it was discovered that African-Americans have lower natriuretic peptide levels compared with whites, raising the possibility that African-Americans individuals can have a relative "natriuretic peptide deficiency" with reduced natriuretic peptide responses to salt loading. However, the prior studies were based on epidemiologic data with individuals on random salt backgrounds. This highlights the need for more detailed physiologic studies, under controlled salt conditions and with standardized assessment of the natriuretic peptide and RAAS and tissue sodium stores.
The aim of this study is to assess the natriuretic peptide response to dietary salt loading in African-American individuals compared with white individuals. This study will test the primary hypothesis that compared with whites, African-American individuals have blunted natriuretic peptide responses to dietary salt loading.
Secondary hypotheses include:
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The low-salt diet (7 days) will consist of meals, snacks, and sodium free water provided by the study staff.
The high-salt diet (7 days) consists of each subject's usual diet, supplemented each day with 2 bouillon broth packets, which will be provided to the subject by the study staff.
Time frame: 4 years
Time frame: 4 years
Measured by sodium MRI
Time frame: 4 years
Time frame: 4 years
Measured by change in mean arterial pressure
Time frame: 4 years
Measured from 24 hour urine collection
Time frame: 4 years
Measured from Echocardiography as tissue Doppler e'
Time frame: 4 years
Physiological parameter
Time frame: 4 years
Physiological parameter
Vanderbilt University
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03434574
Cardiovascular Diseases, Healthy
London, Central London, United Kingdom
View Trial DetailsNCT03178396
Cardiovascular Diseases, Healthy
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT03070184
Cardiovascular Diseases, Healthy
Birmingham, Alabama, United States
View Trial DetailsNCT02705911
Cardiovascular Diseases, Healthy
Leuven, Belgium
View Trial Details